Suppr超能文献

向大鼠静脉注射和肌肉注射载有甲氨蝶呤的带正电荷脂质体后甲氨蝶呤的药代动力学。

Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotrexate-bearing positively charged liposomes to rats.

作者信息

Kim M M, Lee S H, Lee M G, Hwang S J, Kim C K

机构信息

College of Pharmacy, Seoul National University, Kwanak-Gu, Korea.

出版信息

Biopharm Drug Dispos. 1995 May;16(4):279-93. doi: 10.1002/bdd.2510160404.

Abstract

The pharmacokinetics and tissue distribution of methotrexate (MTX) were investigated after intravenous (IV) and intramuscular (IM) injection of free MTX (treatment I), freshly prepared MTX-bearing positively charged liposomes (large unilamellar vesicles), PLUVs (treatment II), and empty PLUVs mixed manually with free MTX (treatment III), 4 mg kg-1 as free MTX to rats, using HPLC assay. After 1 min IV infusion, the plasma concentrations of MTX (Cp), the area under the plasma concentration-time curve (AUC, 173 against 314 micrograms mL min-1), the terminal half-life (t1/2, 24.0 against 412 min), the mean residence time (MRT, 13.0 against 324 min), and the apparent volume of distribution at steady state (VSS, 289 against 3370 mL kg-1) were significantly larger, but the total body clearance (CL, 23.1 against 12.8 mL min-1 kg-1), the renal clearance (CLR, 8.38 against 3.09 mL min-1 kg-1), the non-renal clearance (CLNR, 14.6 against 9.56 mL min-1 kg-1), and the amount of MTX excreted in urine (Xu, 415 against 275 micrograms) were significantly lower in treatment II than in treatment I. This could be due to the fact that some of the MTX-bearing PLUVs were entrapped in tissues and the rest were present in plasma (larger MRT and Vss in treatment II), and MTX is slowly released from MTX-bearing PLUVs (longer t1/2 in treatment II). In the present HPLC assay, the concentrations of MTX represent the sum of free MTX and MTX in MTX-bearing PLUVs (larger Cp and AUC and slower CL in treatment II). Saturable formation of 7-hydroxymethotrexate from MTX was reported in rabbit blood and nonlinear disposition of MTX was also reported in rats and rabbits (lower Xu and CLR in treatment II). After 1 min IV infusion, some pharmacokinetic parameters of MTX, such as AUC, CL, CLR, CLNR, and Xu, were significantly different between treatments I and III, but nonetheless the differences were smaller than those between treatments I and II. After both IV and IM administration, the amount of MTX remaining per gram of tissue or organ in the kidney, stomach, small intestine, and large intestine was significantly smaller in treatment II than in treatment I.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

采用高效液相色谱法(HPLC),以4mg/kg游离甲氨蝶呤(MTX)的剂量,分别对大鼠静脉注射(IV)和肌肉注射(IM)游离MTX(治疗I)、新制备的载MTX正电荷脂质体(大单层囊泡,PLUVs,治疗II)以及将空PLUVs与游离MTX手动混合(治疗III)后的MTX药代动力学和组织分布进行了研究。静脉输注1分钟后,治疗II组MTX的血浆浓度(Cp)、血浆浓度-时间曲线下面积(AUC,分别为173和314μg·mL·min⁻¹)、末端半衰期(t1/2,分别为24.0和412分钟)、平均驻留时间(MRT,分别为13.0和324分钟)以及稳态表观分布容积(VSS,分别为289和3370mL/kg)显著更高,但总体清除率(CL,分别为23.1和12.8mL·min⁻¹·kg⁻¹)、肾清除率(CLR,分别为8.38和3.09mL·min⁻¹·kg⁻¹)、非肾清除率(CLNR,分别为14.6和9.56mL·min⁻¹·kg⁻¹)以及尿中MTX排泄量(Xu,分别为415和275μg)显著低于治疗I组。这可能是因为一些载MTX的PLUVs滞留在组织中,其余的存在于血浆中(治疗II组MRT和Vss更大),并且MTX从载MTX的PLUVs中缓慢释放(治疗II组t1/2更长)。在本HPLC分析中,MTX的浓度代表游离MTX和载MTX的PLUVs中MTX的总和(治疗II组Cp和AUC更大,CL更慢)。据报道,兔血中MTX可饱和形成7-羟基甲氨蝶呤,大鼠和兔中也报道了MTX的非线性处置(治疗II组Xu和CLR更低)。静脉输注1分钟后,治疗I组和III组MTX的一些药代动力学参数,如AUC、CL、CLR、CLNR和Xu,存在显著差异,但差异小于治疗I组和II组之间的差异。静脉注射和肌肉注射后,治疗II组肾脏、胃、小肠和大肠中每克组织或器官中剩余的MTX量显著低于治疗I组。(摘要截短至400字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验